Both studies have completed enrollment right now, with more than 1,400 patients enrolled through 210 study sites globally. Allen, M.D., Ph.D., executive vice president and chief medical officer of AMAG. As we comprehensive data collection and evaluation over the next few months, the results of these studies will form the foundation for global regulatory submissions, which will seek to expand the indication of Feraheme for the treatment of IDA beyond the current indication for adult sufferers with persistent kidney disease. AMAG programs to submit a sNDA for the broader U.S.In addition, if they applied the same death count to all or any 8500 nurses and midwives serving in the public sector in Zambia in 2000, they discovered the amount of deaths would be nearly double the Zambian nurses who requested registration in the UK in 2003-04. Related StoriesClinical trial suggests HIV sufferers should start therapy sooner instead of laterCountering Ebola misinformation: an interview with Dr Katie Geary, International SOSDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEFeeley calls on governments to make antiretrovirals more available and convenient to handle premature deaths in the civil services. In his Comment, he lists components for governments to consider in programmes to tackle this problem, such as unique provision for treatment in remote control locations.